Brief: Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting
18/06/2024 12:14
June 18 (Reuters) - Clene Inc. CLNN.O :
* CLENE PRESENTS EXTENDED SURVIVAL DATA THROUGH 3.5 YEARS
AND NEW
NFL RESPONDER RESULTS WITH CNM-AU8® 30 MG TREATMENT FROM
THE HEALEY ALS PLATFORM TRIAL OPEN LABEL EXTENSION AT THE 2024
ENCALS MEETING
* CLENE INC.: MORE THAN 650 PATIENT YEARS OF CNM-AU8
TREATMENT
EXPOSURE WITHOUT ANY IDENTIFIED SAFETY SIGNALS
Source text for Eikon: ID:nGNX460gLV
Further company coverage: CLNN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clene
See all newsClene Inc reports results for the quarter ended June 30 - Earnings Summary
Clene Q2 net loss widens on higher other expenses
Clene Inc expected to post a loss of 37 cents a share - Earnings Preview
Brief: Clene Inc - Enters Second Amendment To Senior Secured Convertible Notes - SEC Filing
Clene Q1 loss widens on warrant liability issuance costs